Feds buy more monoclonal antibody drug for pre-exposure
The U.S. government has purchased an additional 500,000 doses of Evusheld, AstraZeneca's monoclonal antibody drug, to be given before exposure to COVID-19, the company announced. This is on top of the 700,000 Evusheld doses already purchased.
White House officials previously said over 500,000 doses would be stockpiled in January and "significantly more" would be purchased by March."
Evusheld was authorized in December 2021 and is the first monoclonal therapy meant to be used in advance of an eligible person's exposure to COVID-19.
However, it's not meant for a wide group of people: this therapy is only authorized for immunocompromised people who may not have developed an optimal immune response to their vaccine. This therapy is also for people with a history of severe adverse reactions to a COVID-19 vaccine and thus aren't recommended to get vaccinated.
Evusheld is not authorized as a way to treat COVID-19 after testing positive.
-ABC News' Sasha Pezenik